Device Thrombosis

Compared with metallic drug-eluting stents, a first-generation everolimus-eluting bioresorbable vascular scaffold had similar 5-year rates of death, patient-oriented composite events, angina recurrence and quality of life, data show.

SAN FRANCISCO — Among patients who underwent transcatheter valve-in-valve repair of a failed surgical mitral valve, those who had transseptal access had lower mortality than those who had transapical access at 1 year, according to data presented at TCT 2019.